LPCN

Lipocine Inc. (LPCN) Economic Moat Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-09-01

Overall Score

Scale Market Position

Micro-cap size limits competitive leverage and bargaining power.

Revenue base remains very small, with TTM revenue per share at 0.19 and market cap around $20.1M.

Pricing Power Margins

Gross margin is extremely high at 98.1%, but operating margin remains deeply negative at -8.0%.

Negative net profit margin of -7.6% indicates the company is not yet converting product economics into durable earnings power.

Capital Efficiency Returns

Returns remain deeply negative, with ROIC at -57.7% and ROE at -64.7%.

Asset efficiency is weak despite a high fixed-asset turnover, as overall asset turnover is only 0.07.

Balance Sheet Resilience

Liquidity is strong, with current and quick ratios both at 11.5x and cash per share of 2.83.

The company carries no debt, which reduces financial risk and supports optionality.

Moat Durability Intangibles

No clear evidence of durable moat sources such as brand, switching costs, or network effects.

R&D intensity is high at 6.5% of revenue, but current losses suggest innovation is not yet translating into defensible economics.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lipocine Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →